Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BHVN 
Biohaven Pharmaceutical Holding Co Ltd (BHVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: BHVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $42.13
1 Year Target Price $42.13
| 11 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.05% | Avg. Invested days 45 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 902.40M USD | Price to earnings Ratio - | 1Y Target Price 42.13 |
Price to earnings Ratio - | 1Y Target Price 42.13 | ||
Volume (30-day avg) 16 | Beta 3.45 | 52 Weeks Range 7.63 - 54.53 | Updated Date 11/7/2025 |
52 Weeks Range 7.63 - 54.53 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -103.41% | Return on Equity (TTM) -295.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1527401363 | Price to Sales(TTM) - |
Enterprise Value 1527401363 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.19 | Shares Outstanding 105790997 | Shares Floating 88380749 |
Shares Outstanding 105790997 | Shares Floating 88380749 | ||
Percent Insiders 11.55 | Percent Institutions 76.72 |
Upturn AI SWOT
Biohaven Pharmaceutical Holding Co Ltd
Company Overview
History and Background
Biohaven Pharmaceutical Holding Co. Ltd. was founded in 2013. It focused on developing and commercializing therapies for neurological and neuropsychiatric diseases. It achieved significant milestones with its Nurtec ODT migraine medication before being acquired by Pfizer.
Core Business Areas
- Migraine: Development and commercialization of migraine therapies, primarily Nurtec ODT (rimegepant).
- Neurology: Research and development of treatments for other neurological disorders.
Leadership and Structure
Before acquisition, the leadership team was headed by Vlad Coric, MD, as CEO. The organizational structure included departments for research, development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- Nurtec ODT (rimegepant): An orally disintegrating tablet for the acute treatment and preventive treatment of migraine. Before being acquired by Pfizer, it was estimated to have around 25% market share of the migraine treatment market (acute + preventative), with revenue around $650 million in 2022. Competitors include Ubrelvy (ubrogepant) by AbbVie, Qulipta (atogepant) also by AbbVie, and Aimovig (erenumab-aooe) by Amgen.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a focus on developing innovative therapies for unmet medical needs. The migraine treatment market has seen rapid growth. It is currently estimated to be between 8-10B USD.
Positioning
Before the Pfizer acquisition, Biohaven was a key player in the migraine treatment market due to the success of Nurtec ODT. They distinguished themselves with an oral, non-opioid treatment option.
Total Addressable Market (TAM)
The migraine market is significant with an estimated TAM of $8-10 billion. Biohaven, through Nurtec ODT, captured a growing share before acquisition, positioning them for significant market penetration and continued growth if they remained independent.
Upturn SWOT Analysis
Strengths
- Successful product (Nurtec ODT)
- Strong brand recognition (Before the PFE acquisition)
- Innovation in migraine treatment
- Established distribution network
Weaknesses
- Reliance on a single key product (Nurtec ODT)
- High R&D costs
- Competition from larger pharmaceutical companies
- Regulatory risks
Opportunities
- Expansion into new markets
- Development of new therapies for other neurological disorders
- Partnerships and collaborations
- Further clinical trials to expand Nurtec ODT's uses
Threats
- Competition from existing and new migraine treatments
- Patent expiration
- Changes in regulatory landscape
- Pricing pressures from insurers
Competitors and Market Share
Key Competitors
- ABBV
- AMGN
- LLY
Competitive Landscape
Before acquisition, Biohaven differentiated itself with an oral CGRP antagonist. It competed against established pharmaceutical companies with broader portfolios and larger marketing budgets.
Major Acquisitions
Pfizer
- Year: 2022
- Acquisition Price (USD millions): 11600
- Strategic Rationale: Pfizer acquired Biohaven to expand its portfolio of innovative therapies for neurological disorders, specifically adding Nurtec ODT to its offerings.
Growth Trajectory and Initiatives
Historical Growth: Biohaven experienced rapid growth due to the success of Nurtec ODT. Prior to acquisition, analysts were forecasting continued growth based on market penetration and potential label expansion.
Future Projections: Future projections depend on Pfizer's plans for Nurtec ODT and other Biohaven assets.
Recent Initiatives: Before acquisition, Biohaven focused on expanding Nurtec ODT's market share, developing new formulations, and advancing other pipeline programs.
Summary
Biohaven was a rapidly growing pharmaceutical company focused on migraine treatment, primarily known for Nurtec ODT. Its success led to its acquisition by Pfizer for $11.6 billion. Before the acquisition, the company faced competition from larger pharma companies and relied heavily on a single product. Its strengths included innovative therapy and established distribution network, while its weaknesses were its reliance on one product and high R&D costs. Pfizer will need to navigate the competitive landscape and pricing pressures.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
- Press releases
- Pfizer News Releases
Disclaimers:
This analysis is based on publicly available information and analyst estimates. The data is subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biohaven Pharmaceutical Holding Co Ltd
Exchange NYSE | Headquaters New Haven, CT, United States | ||
IPO Launch date 2022-09-23 | Chairman & CEO Dr. Vladimir Coric M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 256 | Website https://www.biohaven.com |
Full time employees 256 | Website https://www.biohaven.com | ||
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.